Related Experiment Video

Updated: Jun 7, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

The clinical problem of hyperinsulinemic hypoglycemia and resultant infantile spasms

Anitha Kumaran1, Sri Kar, Ritika R Kapoor

  • 1Developmental Endocrinology Research Group, Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, 30 Guilford St, London WC1N 1EH, United Kingdom.

Pediatrics
|October 20, 2010
PubMed

Insights

Neonatal hyperinsulinemic hypoglycemia (HH) can lead to infantile spasms, a rare but serious condition. Long-term neurodevelopmental follow-up is crucial for affected infants.

Area of Science:

  • Pediatric Neurology
  • Endocrinology
  • Neonatology

Background:

  • Hyperinsulinemic hypoglycemia (HH) is a significant cause of severe hypoglycemia in neonates and infants.
  • HH is associated with substantial risks of neurologic handicap and epilepsy.

Observation:

  • This study reports on 5 patients with neonatal-onset HH who developed infantile spasms.
  • Infantile spasms presented at a mean age of 6.6 months, often in clusters.
  • Hypsarrhythmia on EEG was present in 3/5 patients; brain MRI revealed structural abnormalities in only 1/4.

Findings:

  • Neonatal HH, regardless of severity, is linked to the later development of infantile spasms.
  • A variable latent period exists between HH onset and the development of spasms.
  • All patients exhibited developmental delay.

Implications:

  • Early recognition and management of neonatal HH are critical to mitigate potential long-term neurologic sequelae.
  • Extended neurodevelopmental surveillance, up to one year of age, is recommended for infants with a history of neonatal HH.
  • This association highlights the need for comprehensive care and monitoring for infants affected by hyperinsulinemic hypoglycemia.

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes: